Involvement of canonical and non-canonical D1 dopamine receptor signalling pathways in L-dopa-induced dyskinesia
Chronic L-3,4-dihydroxyphenylalanine (L-dopa) treatment of Parkinson Disease (PD) often leads to debilitating involuntary movements, termed L-dopa-induced dyskinesia (LID). The past few years have seen an unprecedented increase in understanding the neural mechanisms underlying LID manifestation in P...
Uloženo v:
| Vydáno v: | Parkinsonism & related disorders Ročník 15; s. S64 - S67 |
|---|---|
| Hlavní autoři: | , |
| Médium: | Journal Article |
| Jazyk: | angličtina |
| Vydáno: |
England
Elsevier Ltd
01.12.2009
|
| Témata: | |
| ISSN: | 1353-8020, 1873-5126, 1873-5126 |
| On-line přístup: | Získat plný text |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|
| Abstract | Chronic L-3,4-dihydroxyphenylalanine (L-dopa) treatment of Parkinson Disease (PD) often leads to debilitating involuntary movements, termed L-dopa-induced dyskinesia (LID). The past few years have seen an unprecedented increase in understanding the neural mechanisms underlying LID manifestation in PD associating them mostly with D1 dopamine (DA) receptor sensitisation and deregulated homologous desensitisation as well as hyperactivity of both canonical and non-canonical DA signalling pathways. We here review these recent findings and demonstrate that decreasing DA receptor-mediated signalling (i) by increasing D1 receptor internalization and (ii) by inhibiting the Ras-Extracellular signal-Regulated Kinase 1/2 non-canonical DA signalling cascade, might reduced LID severity. Strategy (i) uses the lentivirus-mediated over-expression of the G protein-coupled receptor kinase 6 that control the desensitisation of DA receptors. Strategy (ii) proposes to use statins that, besides being specific inhibitors of the rate-limiting enzyme in cholesterol biosynthesis, can also inhibit Ras isoprenylation and activity and subsequently the phosphorylation of ERK1/2. Experiments were performed in both the rodent and primate models of LID. Those results strongly suggest that different strategies might represent a treatment option for managing LID in PD. |
|---|---|
| AbstractList | Chronic L-3,4-dihydroxyphenylalanine (L-dopa) treatment of Parkinson Disease (PD) often leads to debilitating involuntary movements, termed L-dopa-induced dyskinesia (LID). The past few years have seen an unprecedented increase in understanding the neural mechanisms underlying LID manifestation in PD associating them mostly with D1 dopamine (DA) receptor sensitisation and deregulated homologous desensitisation as well as hyperactivity of both canonical and non-canonical DA signalling pathways. We here review these recent findings and demonstrate that decreasing DA receptor-mediated signalling (i) by increasing D1 receptor internalization and (ii) by inhibiting the Ras-Extracellular signal-Regulated Kinase 1/2 non-canonical DA signalling cascade, might reduced LID severity. Strategy (i) uses the lentivirus-mediated over-expression of the G protein-coupled receptor kinase 6 that control the desensitisation of DA receptors. Strategy (ii) proposes to use statins that, besides being specific inhibitors of the rate-limiting enzyme in cholesterol biosynthesis, can also inhibit Ras isoprenylation and activity and subsequently the phosphorylation of ERK1/2. Experiments were performed in both the rodent and primate models of LID. Those results strongly suggest that different strategies might represent a treatment option for managing LID in PD. Chronic L-3,4-dihydroxyphenylalanine (L-dopa) treatment of Parkinson Disease (PD) often leads to debilitating involuntary movements, termed L-dopa-induced dyskinesia (LID). The past few years have seen an unprecedented increase in understanding the neural mechanisms underlying LID manifestation in PD associating them mostly with D1 dopamine (DA) receptor sensitisation and deregulated homologous desensitisation as well as hyperactivity of both canonical and non-canonical DA signalling pathways. We here review these recent findings and demonstrate that decreasing DA receptor-mediated signalling (i) by increasing D1 receptor internalization and (ii) by inhibiting the Ras-Extracellular signal-Regulated Kinase 1/2 non-canonical DA signalling cascade, might reduced LID severity. Strategy (i) uses the lentivirus-mediated over-expression of the G protein-coupled receptor kinase 6 that control the desensitisation of DA receptors. Strategy (ii) proposes to use statins that, besides being specific inhibitors of the rate-limiting enzyme in cholesterol biosynthesis, can also inhibit Ras isoprenylation and activity and subsequently the phosphorylation of ERK1/2. Experiments were performed in both the rodent and primate models of LID. Those results strongly suggest that different strategies might represent a treatment option for managing LID in PD.Chronic L-3,4-dihydroxyphenylalanine (L-dopa) treatment of Parkinson Disease (PD) often leads to debilitating involuntary movements, termed L-dopa-induced dyskinesia (LID). The past few years have seen an unprecedented increase in understanding the neural mechanisms underlying LID manifestation in PD associating them mostly with D1 dopamine (DA) receptor sensitisation and deregulated homologous desensitisation as well as hyperactivity of both canonical and non-canonical DA signalling pathways. We here review these recent findings and demonstrate that decreasing DA receptor-mediated signalling (i) by increasing D1 receptor internalization and (ii) by inhibiting the Ras-Extracellular signal-Regulated Kinase 1/2 non-canonical DA signalling cascade, might reduced LID severity. Strategy (i) uses the lentivirus-mediated over-expression of the G protein-coupled receptor kinase 6 that control the desensitisation of DA receptors. Strategy (ii) proposes to use statins that, besides being specific inhibitors of the rate-limiting enzyme in cholesterol biosynthesis, can also inhibit Ras isoprenylation and activity and subsequently the phosphorylation of ERK1/2. Experiments were performed in both the rodent and primate models of LID. Those results strongly suggest that different strategies might represent a treatment option for managing LID in PD. Summary Chronic L-3,4-dihydroxyphenylalanine (L-dopa) treatment of Parkinson Disease (PD) often leads to debilitating involuntary movements, termed L-dopa-induced dyskinesia (LID). The past few years have seen an unprecedented increase in understanding the neural mechanisms underlying LID manifestation in PD associating them mostly with D1 dopamine (DA) receptor sensitisation and deregulated homologous desensitisation as well as hyperactivity of both canonical and non-canonical DA signalling pathways. We here review these recent findings and demonstrate that decreasing DA receptor-mediated signalling (i) by increasing D1 receptor internalization and (ii) by inhibiting the Ras-Extracellular signal-Regulated Kinase 1/2 non-canonical DA signalling cascade, might reduced LID severity. Strategy (i) uses the lentivirus-mediated over-expression of the G protein-coupled receptor kinase 6 that control the desensitisation of DA receptors. Strategy (ii) proposes to use statins that, besides being specific inhibitors of the rate-limiting enzyme in cholesterol biosynthesis, can also inhibit Ras isoprenylation and activity and subsequently the phosphorylation of ERK1/2. Experiments were performed in both the rodent and primate models of LID. Those results strongly suggest that different strategies might represent a treatment option for managing LID in PD. |
| Author | Guigoni, Céline Bezard, Erwan |
| Author_xml | – sequence: 1 givenname: Céline surname: Guigoni fullname: Guigoni, Céline – sequence: 2 givenname: Erwan surname: Bezard fullname: Bezard, Erwan email: erwan.bezard@u-bordeaux2.fr |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/20083011$$D View this record in MEDLINE/PubMed |
| BookMark | eNqNkc1u1DAUhS1URNuBRwB5R1kE_DOJEyGKUIG20kgsgLV1x74pbhM72MmgeXucmRakSqisfGWd8_n6nGNy4INHQp5z9pozXr35ymUpi5oJdsKaV4qpWhbqETnitZJFyUV1kOc7ySE5TumaMaZKJp-QQ8FYLRnnR2S49JvQbbBHP9LQUgP5HWego-AtzXPx9-YjpzYM0DuPNKLBYQyRJnfloeucv6IDjD9-wTZR5-mqmKWF83YyaKndpptsSw6eksctdAmf3Z4L8v3zp29nF8Xqy_nl2YdVYZZKjkUt182yyasbEFhZwRTkTwnkrWgqYWCpamhFq6CtxdJUxkCzVliWFq2t-FrKBXm55w4x_Jwwjbp3yWDXgccwJa2krGXVVLPyxa1yWvdo9RBdD3Gr70LKgnIvMDGkFLH9I-FMz2XoXRl6TlqzRu_KyA8syNt7PuNGGF3wYwTXPeh-v3djTmnjMOpkHPqcpsvhj9oG9yDh9B7B5J7mKm9wi-k6TDFXlzTXSWi2h8wM1uwIM-DdvwH_scBv8C3MLA |
| CitedBy_id | crossref_primary_10_1002_mds_29055 crossref_primary_10_1111_ejn_14119 crossref_primary_10_1016_j_neubiorev_2015_07_010 crossref_primary_10_1186_1741_7015_11_76 crossref_primary_10_1515_rns_2011_012 crossref_primary_10_1016_j_nbd_2014_08_006 crossref_primary_10_1007_s12035_025_04720_z crossref_primary_10_1016_j_parkreldis_2016_12_003 crossref_primary_10_1016_j_jneumeth_2011_02_012 crossref_primary_10_1002_brb3_867 crossref_primary_10_1155_2012_640815 crossref_primary_10_1016_j_bbr_2016_06_003 crossref_primary_10_1016_j_neubiorev_2019_05_008 |
| Cites_doi | 10.1016/S1471-1931(00)00028-8 10.1002/ana.20296 10.1523/JNEUROSCI.5884-08.2009 10.1523/JNEUROSCI.4720-07.2008 10.1056/NEJM196902132800701 10.1038/35086062 10.1016/j.nbd.2008.11.010 10.1523/JNEUROSCI.0676-04.2004 10.1111/j.1471-4159.2008.05831.x 10.1016/j.nbd.2007.02.001 10.1523/JNEUROSCI.0852-07.2007 10.1126/science.2147780 10.1073/pnas.94.7.3363 10.1038/nm875 10.1074/jbc.M710349200 10.1046/j.1471-4159.2003.01600.x 10.1038/nrn2471 10.1016/j.nbd.2004.10.005 10.1016/0166-2236(90)90107-L 10.1046/j.1460-9568.2000.00089.x 10.1523/JNEUROSCI.2582-06.2006 10.1212/WNL.54.8.1589 10.1523/JNEUROSCI.3952-07.2008 10.1111/j.1460-9568.2008.06387.x 10.1126/scitranslmed.3000664 10.1523/JNEUROSCI.22-12-05042.2002 10.1038/nn1040 10.1016/j.biopsych.2005.05.044 10.1124/mol.107.043885 |
| ContentType | Journal Article |
| Copyright | 2009 Elsevier Ltd Elsevier Ltd |
| Copyright_xml | – notice: 2009 Elsevier Ltd – notice: Elsevier Ltd |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 |
| DOI | 10.1016/S1353-8020(09)70783-7 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic MEDLINE |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1873-5126 |
| EndPage | S67 |
| ExternalDocumentID | 20083011 10_1016_S1353_8020_09_70783_7 S1353802009707837 1_s2_0_S1353802009707837 |
| Genre | Research Support, Non-U.S. Gov't Journal Article Review |
| GroupedDBID | --- --K --M .1- .FO .~1 0R~ 123 1B1 1P~ 1~. 1~5 29O 4.4 457 4G. 53G 5VS 7-5 71M 8P~ AAEDT AAEDW AAIKJ AAKOC AALRI AAOAW AAQFI AAQXK AATTM AAWTL AAXKI AAXLA AAXUO AAYWO ABBQC ABCQJ ABFNM ABGSF ABIVO ABJNI ABMAC ABMZM ABTEW ABUDA ABWVN ABXDB ACDAQ ACGFO ACGFS ACIEU ACIUM ACLOT ACRLP ACRPL ACVFH ADBBV ADCNI ADEZE ADMUD ADNMO ADUVX AEBSH AEHWI AEIPS AEKER AENEX AEUPX AEVXI AFJKZ AFPUW AFRHN AFTJW AFXIZ AGHFR AGQPQ AGRDE AGUBO AGWIK AGYEJ AIEXJ AIGII AIIUN AIKHN AITUG AJRQY AJUYK AKBMS AKRWK AKYEP ALMA_UNASSIGNED_HOLDINGS AMRAJ ANKPU ANZVX APXCP ASPBG AVWKF AXJTR AZFZN BKOJK BLXMC BNPGV CS3 DU5 EBS EFJIC EFKBS EFLBG EJD EO8 EO9 EP2 EP3 F5P FDB FEDTE FGOYB FIRID FNPLU FYGXN G-Q GBLVA HVGLF HZ~ IHE J1W KOM M41 MO0 MOBAO N9A O-L O9- OAUVE OP~ OZT P-8 P-9 P2P PC. Q38 R2- ROL RPZ SCC SDF SDG SDP SEL SES SEW SPCBC SSH SSN SSU SSZ T5K Z5R ~G- ~HD AACTN AFCTW AFKWA AJOXV AMFUW RIG AADPK AAIAV ABLVK ABYKQ AJBFU DOVZS LCYCR 9DU AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 |
| ID | FETCH-LOGICAL-c473t-83b949020ca2e6d207a5122e1f2962ca478af2f7af824c6cca9b7e55dedd61b33 |
| ISICitedReferencesCount | 13 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000576252500015&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1353-8020 1873-5126 |
| IngestDate | Wed Oct 01 13:09:46 EDT 2025 Wed Feb 19 01:52:00 EST 2025 Tue Nov 18 21:04:21 EST 2025 Sat Nov 29 04:14:43 EST 2025 Fri Feb 23 02:20:31 EST 2024 Sun Feb 23 10:19:55 EST 2025 Tue Oct 14 19:36:42 EDT 2025 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Keywords | AC D3R Parkinson's disease AMPA L-dopa D1R D2R Trafficking LID RGSL DARPP-32 MSN 6-OHDA SNc cAMP Sensitisation AIMs PD GPCR Dopamine D1 receptor MPTP DA Abnormal involuntary movements ERK extracellular signal-regulated kinase cyclic adenosine 3′,5′-monophosphate D1 dopamine receptor G protein-coupled receptors l-3,4-dihydroxyphenylalanine adenylyl cyclase L-dopa-induced dyskinesia regulatory GPCR signalling protein D2 dopamine receptor dopamine and cyclic adenosine 3′,5′-monophosphate-regulated phosphoprotein, 32 kDa substantia nigra pars compacta D3 dopamine receptor 6-hydroxydopamine α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine medium spiny neurons dopamine |
| Language | English |
| License | https://www.elsevier.com/tdm/userlicense/1.0 |
| LinkModel | OpenURL |
| MergedId | FETCHMERGED-LOGICAL-c473t-83b949020ca2e6d207a5122e1f2962ca478af2f7af824c6cca9b7e55dedd61b33 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 ObjectType-Review-3 content type line 23 |
| PMID | 20083011 |
| PQID | 733836963 |
| PQPubID | 23479 |
| ParticipantIDs | proquest_miscellaneous_733836963 pubmed_primary_20083011 crossref_primary_10_1016_S1353_8020_09_70783_7 crossref_citationtrail_10_1016_S1353_8020_09_70783_7 elsevier_sciencedirect_doi_10_1016_S1353_8020_09_70783_7 elsevier_clinicalkeyesjournals_1_s2_0_S1353802009707837 elsevier_clinicalkey_doi_10_1016_S1353_8020_09_70783_7 |
| PublicationCentury | 2000 |
| PublicationDate | 2009-12-01 |
| PublicationDateYYYYMMDD | 2009-12-01 |
| PublicationDate_xml | – month: 12 year: 2009 text: 2009-12-01 day: 01 |
| PublicationDecade | 2000 |
| PublicationPlace | England |
| PublicationPlace_xml | – name: England |
| PublicationTitle | Parkinsonism & related disorders |
| PublicationTitleAlternate | Parkinsonism Relat Disord |
| PublicationYear | 2009 |
| Publisher | Elsevier Ltd |
| Publisher_xml | – name: Elsevier Ltd |
| References | Santini, Valjent, Usiello, Carta, Borgkvist, Girault (bib15) 2007; 27 Guigoni, Doudnikoff, Li, Bloch, Bezard (bib18) 2007; 26 Konitsiotis, Blanchet, Verhagen, Lamers, Chase (bib16) 2000; 54 Alexander, Crutcher (bib5) 1990; 13 Bezard, Ferry, Mach, Stark, Leriche, Boraud (bib21) 2003; 9 Giorgi, D'Angelo, Esposito, Nuccetelli, Sorge, Martorana (bib10) 2008; 28 Santini, Alcacer, Cacciatore, Heiman, Herve, Greengarda (bib29) 2009; 108 Bordet, Ridray, Carboni, Diaz, Sokoloff, Schwartz (bib22) 1997; 94 Schuster, Nadjar, Guo, Li, Ittrich, Hengerer (bib30) 2008; 28 Gerfen, Paletzki, Worley (bib31) 2008; 28 Corvol, Muriel, Valjent, Feger, Hanoun, Girault (bib9) 2004; 24 Bezard, Gross, Qin, Gurevich, Benovic, Gurevich (bib19) 2005; 18 Cotzias, Papavasiliou, Gellene (bib1) 1969; 280 Aubert, Guigoni, Hakansson, Li, Dovero, Barthe (bib8) 2005; 57 Gerfen, Engber, Mahan, Susel, Chase, Monsma (bib6) 1990; 250 Bordet, Ridray, Schwartz, Sokoloff (bib20) 2000; 12 Gerfen, Miyachi, Paletzki, Brown (bib27) 2002; 22 Picconi, Centonze, Hakansson, Bernardi, Greengard, Fisone (bib13) 2003; 6 Berthet, Porras, Doudnikoff, Stark, Cador, Bezard (bib17) 2009; 29 Hossain, Weiner (bib11) 1993; 267 Fiorentini, Busi, Gorruso, Gotti, Spano, Missale (bib24) 2008; 74 Obeso, Rodriguez-Oroz, Rodriguez, Lanciego, Artieda, Gonzalo (bib2) 2000; 23 Nadjar, Brotchie, Guigoni, Li, Zhou, Wang (bib7) 2006; 26 Jenner (bib4) 2008; 9 Cao, Guan, Xu, Wang, Sun (bib12) 2006; 22 Marcellino, Ferre, Casado, Cortes, Le Foll, Mazzola (bib25) 2008; 283 Bezard, Brotchie, Gross (bib3) 2001; 2 Ahmed MR, Berthet A, Bychkov E, Li Q, Porras G, Bioulac BH, et al. Lentivirally-mediated overexpression of GRK6 alleviates L-DOPA-induced dyskinesia in experimental Parkinson's disease. In revision 2009. Pavon, Martin, Mendialdua, Moratalla (bib28) 2006; 59 Gross, Ravenscroft, Dovero, Jaber, Bioulac, Bezard (bib23) 2003; 84 Visanji, Fox, Johnston, Reyes, Millan, Brotchie (bib14) 2009; 35 Gerfen (10.1016/S1353-8020(09)70783-7_bib31) 2008; 28 Cao (10.1016/S1353-8020(09)70783-7_bib12) 2006; 22 Jenner (10.1016/S1353-8020(09)70783-7_bib4) 2008; 9 Marcellino (10.1016/S1353-8020(09)70783-7_bib25) 2008; 283 Gerfen (10.1016/S1353-8020(09)70783-7_bib27) 2002; 22 Corvol (10.1016/S1353-8020(09)70783-7_bib9) 2004; 24 Fiorentini (10.1016/S1353-8020(09)70783-7_bib24) 2008; 74 Bordet (10.1016/S1353-8020(09)70783-7_bib22) 1997; 94 Berthet (10.1016/S1353-8020(09)70783-7_bib17) 2009; 29 Gerfen (10.1016/S1353-8020(09)70783-7_bib6) 1990; 250 Aubert (10.1016/S1353-8020(09)70783-7_bib8) 2005; 57 Cotzias (10.1016/S1353-8020(09)70783-7_bib1) 1969; 280 Giorgi (10.1016/S1353-8020(09)70783-7_bib10) 2008; 28 Santini (10.1016/S1353-8020(09)70783-7_bib15) 2007; 27 Nadjar (10.1016/S1353-8020(09)70783-7_bib7) 2006; 26 Alexander (10.1016/S1353-8020(09)70783-7_bib5) 1990; 13 Schuster (10.1016/S1353-8020(09)70783-7_bib30) 2008; 28 Hossain (10.1016/S1353-8020(09)70783-7_bib11) 1993; 267 Santini (10.1016/S1353-8020(09)70783-7_bib29) 2009; 108 Visanji (10.1016/S1353-8020(09)70783-7_bib14) 2009; 35 Bordet (10.1016/S1353-8020(09)70783-7_bib20) 2000; 12 Obeso (10.1016/S1353-8020(09)70783-7_bib2) 2000; 23 Bezard (10.1016/S1353-8020(09)70783-7_bib3) 2001; 2 Bezard (10.1016/S1353-8020(09)70783-7_bib19) 2005; 18 10.1016/S1353-8020(09)70783-7_bib26 Gross (10.1016/S1353-8020(09)70783-7_bib23) 2003; 84 Konitsiotis (10.1016/S1353-8020(09)70783-7_bib16) 2000; 54 Picconi (10.1016/S1353-8020(09)70783-7_bib13) 2003; 6 Bezard (10.1016/S1353-8020(09)70783-7_bib21) 2003; 9 Guigoni (10.1016/S1353-8020(09)70783-7_bib18) 2007; 26 Pavon (10.1016/S1353-8020(09)70783-7_bib28) 2006; 59 |
| References_xml | – volume: 26 start-page: 8653 year: 2006 end-page: 8661 ident: bib7 article-title: Phenotype of striatofugal medium spiny neurons in parkinsonian and dyskinetic nonhuman primates: a call for a reappraisal of the functional organization of the basal ganglia publication-title: J Neurosci – volume: 27 start-page: 6995 year: 2007 end-page: 7005 ident: bib15 article-title: Critical involvement of cAMP/DARPP-32 and extracellular signal-regulated protein kinase signaling in L-DOPA-induced dyskinesia publication-title: J Neurosci – volume: 12 start-page: 2117 year: 2000 end-page: 2123 ident: bib20 article-title: Involvement of the direct striatonigral pathway in levodopa-induced sensitization in 6-hydroxydopamine-lesioned rats publication-title: Eur J Neurosci – volume: 59 start-page: 64 year: 2006 end-page: 74 ident: bib28 article-title: ERK phosphorylation and FosB expression are associated with L-DOPA-induced dyskinesia in hemiparkinsonian mice publication-title: Biol Psychiatry – volume: 280 start-page: 337 year: 1969 end-page: 345 ident: bib1 article-title: Modification of Parkinsonism – chronic treatment with L-dopa publication-title: N Engl J Med – volume: 9 start-page: 665 year: 2008 end-page: 677 ident: bib4 article-title: Molecular mechanisms of L-DOPA-induced dyskinesia publication-title: Nat Rev Neurosci – volume: 267 start-page: 1105 year: 1993 end-page: 1111 ident: bib11 article-title: Dopaminergic functional supersensitivity: effects of chronic L-dopa and carbidopa treatment in an animal model of Parkinson's disease publication-title: J Pharmacol Exp Ther – volume: 35 start-page: 184 year: 2009 end-page: 192 ident: bib14 article-title: Dopamine D3 receptor stimulation underlies the development of L-DOPA-induced dyskinesia in animal models of Parkinson's disease publication-title: Neurobiol Dis – volume: 84 start-page: 1246 year: 2003 end-page: 1255 ident: bib23 article-title: Pattern of levodopa-induced striatal changes is different in normal and MPTP-lesioned mice publication-title: J Neurochem – volume: 22 start-page: 5042 year: 2002 end-page: 5054 ident: bib27 article-title: D1 dopamine receptor supersensitivity in the dopamine-depleted striatum results from a switch in the regulation of ERK1/2/MAP kinase publication-title: J Neurosci – volume: 250 start-page: 1429 year: 1990 end-page: 1432 ident: bib6 article-title: D1 and D2 dopamine receptor-regulated gene expression of striatonigral and striatopallidal neurons publication-title: Science – volume: 28 start-page: 4311 year: 2008 end-page: 4316 ident: bib30 article-title: The 3-hydroxy-3-methylglutaryl-CoA reductase inhibitor lovastatin reduces severity of L-DOPA-induced abnormal involuntary movements in experimental Parkinson's disease publication-title: J Neurosci – volume: 283 start-page: 26016 year: 2008 end-page: 26025 ident: bib25 article-title: Identification of dopamine D1–D3 receptor heteromers: Indications for a role of synergistic D1–D3 receptor interactions in the striatum publication-title: J Biol Chem – volume: 28 start-page: 7113 year: 2008 end-page: 7120 ident: bib31 article-title: Differences between dorsal and ventral striatum in Drd1a dopamine receptor coupling of dopamine-and cAMP-regulated phosphoprotein-32 to activation of extracellular signal-regulated kinase publication-title: J Neurosci – volume: 26 start-page: 452 year: 2007 end-page: 463 ident: bib18 article-title: Altered D(1) dopamine receptor trafficking in parkinsonian and dyskinetic non-human primates publication-title: Neurobiol Dis – volume: 108 start-page: 621 year: 2009 end-page: 633 ident: bib29 article-title: L-DOPA activates ERK signaling and phosphorylates histone H3 in the striatonigral medium spiny neurons of hemiparkinsonian mice publication-title: J Neurochem – volume: 28 start-page: 941 year: 2008 end-page: 950 ident: bib10 article-title: Lowered cAMP and cGMP signalling in the brain during levodopa-induced dyskinesias in hemiparkinsonian rats: new aspects in the pathogenetic mechanisms publication-title: Eur J Neurosci – volume: 54 start-page: 1589 year: 2000 end-page: 1595 ident: bib16 article-title: AMPA receptor blockade improves levodopa-induced dyskinesia in MPTP monkeys publication-title: Neurology – volume: 22 start-page: 159 year: 2006 end-page: 164 ident: bib12 article-title: Mechanism of over-activation in direct pathway mediated by dopamine D(1) receptor in rats with levodopa-induced dyskinesia publication-title: Neurosci Bull – volume: 24 start-page: 7007 year: 2004 end-page: 7014 ident: bib9 article-title: Persistent increase in olfactory type G-protein alpha subunit levels may underlie D1 receptor functional hypersensitivity in Parkinson disease publication-title: J Neurosci – volume: 74 start-page: 59 year: 2008 end-page: 69 ident: bib24 article-title: Reciprocal regulation of dopamine D1 and D3 receptor function and trafficking by heterodimerization publication-title: Mol Pharmacol – volume: 9 start-page: 762 year: 2003 end-page: 767 ident: bib21 article-title: Attenuation of levodopa-induced dyskinesia by normalizing dopamine D3 receptor function publication-title: Nat Med – reference: Ahmed MR, Berthet A, Bychkov E, Li Q, Porras G, Bioulac BH, et al. Lentivirally-mediated overexpression of GRK6 alleviates L-DOPA-induced dyskinesia in experimental Parkinson's disease. In revision 2009. – volume: 6 start-page: 501 year: 2003 end-page: 506 ident: bib13 article-title: Loss of bidirectional striatal synaptic plasticity in L-DOPA-induced dyskinesia publication-title: Nat Neurosci – volume: 29 start-page: 4829 year: 2009 end-page: 4835 ident: bib17 article-title: Pharmacological analysis demonstrates dramatic alteration of D1 Dopamine receptor neuronal distribution in the rat analog of L-DOPA-induced dyskinesia publication-title: J Neurosci – volume: 23 start-page: S8 year: 2000 end-page: 19 ident: bib2 article-title: Pathophysiology of the basal ganglia in Parkinson's disease publication-title: Trends Neurosci – volume: 13 start-page: 266 year: 1990 end-page: 271 ident: bib5 article-title: Functional architecture of basal ganglia circuits: neural substrates of parallel processing publication-title: Trends Neurosci – volume: 94 start-page: 3363 year: 1997 end-page: 3367 ident: bib22 article-title: Induction of dopamine D3 receptor expression as a mechanism of behavioral sensitization to levodopa publication-title: Proc Natl Acad Sci USA – volume: 18 start-page: 323 year: 2005 end-page: 335 ident: bib19 article-title: L-DOPA reverses the MPTP-induced elevation of the arrestin2 and GRK6 expression and enhanced ERK activation in monkey brain publication-title: Neurobiol Dis – volume: 57 start-page: 17 year: 2005 end-page: 26 ident: bib8 article-title: Increased D1 dopamine receptor signaling in levodopa-induced dyskinesia publication-title: Ann Neurol – volume: 2 start-page: 577 year: 2001 end-page: 588 ident: bib3 article-title: Pathophysiology of levodopa-induced dyskinesia: Potential for new therapies publication-title: Nat Rev Neurosci – volume: 23 start-page: S8 issue: 10 Suppl year: 2000 ident: 10.1016/S1353-8020(09)70783-7_bib2 article-title: Pathophysiology of the basal ganglia in Parkinson's disease publication-title: Trends Neurosci doi: 10.1016/S1471-1931(00)00028-8 – volume: 267 start-page: 1105 issue: 3 year: 1993 ident: 10.1016/S1353-8020(09)70783-7_bib11 article-title: Dopaminergic functional supersensitivity: effects of chronic L-dopa and carbidopa treatment in an animal model of Parkinson's disease publication-title: J Pharmacol Exp Ther – volume: 57 start-page: 17 issue: 1 year: 2005 ident: 10.1016/S1353-8020(09)70783-7_bib8 article-title: Increased D1 dopamine receptor signaling in levodopa-induced dyskinesia publication-title: Ann Neurol doi: 10.1002/ana.20296 – volume: 29 start-page: 4829 issue: 15 year: 2009 ident: 10.1016/S1353-8020(09)70783-7_bib17 article-title: Pharmacological analysis demonstrates dramatic alteration of D1 Dopamine receptor neuronal distribution in the rat analog of L-DOPA-induced dyskinesia publication-title: J Neurosci doi: 10.1523/JNEUROSCI.5884-08.2009 – volume: 28 start-page: 4311 issue: 17 year: 2008 ident: 10.1016/S1353-8020(09)70783-7_bib30 article-title: The 3-hydroxy-3-methylglutaryl-CoA reductase inhibitor lovastatin reduces severity of L-DOPA-induced abnormal involuntary movements in experimental Parkinson's disease publication-title: J Neurosci doi: 10.1523/JNEUROSCI.4720-07.2008 – volume: 280 start-page: 337 issue: 7 year: 1969 ident: 10.1016/S1353-8020(09)70783-7_bib1 article-title: Modification of Parkinsonism – chronic treatment with L-dopa publication-title: N Engl J Med doi: 10.1056/NEJM196902132800701 – volume: 2 start-page: 577 year: 2001 ident: 10.1016/S1353-8020(09)70783-7_bib3 article-title: Pathophysiology of levodopa-induced dyskinesia: Potential for new therapies publication-title: Nat Rev Neurosci doi: 10.1038/35086062 – volume: 35 start-page: 184 issue: 2 year: 2009 ident: 10.1016/S1353-8020(09)70783-7_bib14 article-title: Dopamine D3 receptor stimulation underlies the development of L-DOPA-induced dyskinesia in animal models of Parkinson's disease publication-title: Neurobiol Dis doi: 10.1016/j.nbd.2008.11.010 – volume: 24 start-page: 7007 issue: 31 year: 2004 ident: 10.1016/S1353-8020(09)70783-7_bib9 article-title: Persistent increase in olfactory type G-protein alpha subunit levels may underlie D1 receptor functional hypersensitivity in Parkinson disease publication-title: J Neurosci doi: 10.1523/JNEUROSCI.0676-04.2004 – volume: 108 start-page: 621 issue: 3 year: 2009 ident: 10.1016/S1353-8020(09)70783-7_bib29 article-title: L-DOPA activates ERK signaling and phosphorylates histone H3 in the striatonigral medium spiny neurons of hemiparkinsonian mice publication-title: J Neurochem doi: 10.1111/j.1471-4159.2008.05831.x – volume: 26 start-page: 452 issue: 2 year: 2007 ident: 10.1016/S1353-8020(09)70783-7_bib18 article-title: Altered D(1) dopamine receptor trafficking in parkinsonian and dyskinetic non-human primates publication-title: Neurobiol Dis doi: 10.1016/j.nbd.2007.02.001 – volume: 22 start-page: 159 issue: 3 year: 2006 ident: 10.1016/S1353-8020(09)70783-7_bib12 article-title: Mechanism of over-activation in direct pathway mediated by dopamine D(1) receptor in rats with levodopa-induced dyskinesia publication-title: Neurosci Bull – volume: 27 start-page: 6995 issue: 26 year: 2007 ident: 10.1016/S1353-8020(09)70783-7_bib15 article-title: Critical involvement of cAMP/DARPP-32 and extracellular signal-regulated protein kinase signaling in L-DOPA-induced dyskinesia publication-title: J Neurosci doi: 10.1523/JNEUROSCI.0852-07.2007 – volume: 250 start-page: 1429 year: 1990 ident: 10.1016/S1353-8020(09)70783-7_bib6 article-title: D1 and D2 dopamine receptor-regulated gene expression of striatonigral and striatopallidal neurons publication-title: Science doi: 10.1126/science.2147780 – volume: 94 start-page: 3363 issue: 7 year: 1997 ident: 10.1016/S1353-8020(09)70783-7_bib22 article-title: Induction of dopamine D3 receptor expression as a mechanism of behavioral sensitization to levodopa publication-title: Proc Natl Acad Sci USA doi: 10.1073/pnas.94.7.3363 – volume: 9 start-page: 762 issue: 6 year: 2003 ident: 10.1016/S1353-8020(09)70783-7_bib21 article-title: Attenuation of levodopa-induced dyskinesia by normalizing dopamine D3 receptor function publication-title: Nat Med doi: 10.1038/nm875 – volume: 283 start-page: 26016 issue: 38 year: 2008 ident: 10.1016/S1353-8020(09)70783-7_bib25 article-title: Identification of dopamine D1–D3 receptor heteromers: Indications for a role of synergistic D1–D3 receptor interactions in the striatum publication-title: J Biol Chem doi: 10.1074/jbc.M710349200 – volume: 84 start-page: 1246 issue: 6 year: 2003 ident: 10.1016/S1353-8020(09)70783-7_bib23 article-title: Pattern of levodopa-induced striatal changes is different in normal and MPTP-lesioned mice publication-title: J Neurochem doi: 10.1046/j.1471-4159.2003.01600.x – volume: 9 start-page: 665 issue: 9 year: 2008 ident: 10.1016/S1353-8020(09)70783-7_bib4 article-title: Molecular mechanisms of L-DOPA-induced dyskinesia publication-title: Nat Rev Neurosci doi: 10.1038/nrn2471 – volume: 18 start-page: 323 issue: 2 year: 2005 ident: 10.1016/S1353-8020(09)70783-7_bib19 article-title: L-DOPA reverses the MPTP-induced elevation of the arrestin2 and GRK6 expression and enhanced ERK activation in monkey brain publication-title: Neurobiol Dis doi: 10.1016/j.nbd.2004.10.005 – volume: 13 start-page: 266 year: 1990 ident: 10.1016/S1353-8020(09)70783-7_bib5 article-title: Functional architecture of basal ganglia circuits: neural substrates of parallel processing publication-title: Trends Neurosci doi: 10.1016/0166-2236(90)90107-L – volume: 12 start-page: 2117 issue: 6 year: 2000 ident: 10.1016/S1353-8020(09)70783-7_bib20 article-title: Involvement of the direct striatonigral pathway in levodopa-induced sensitization in 6-hydroxydopamine-lesioned rats publication-title: Eur J Neurosci doi: 10.1046/j.1460-9568.2000.00089.x – volume: 26 start-page: 8653 issue: 34 year: 2006 ident: 10.1016/S1353-8020(09)70783-7_bib7 article-title: Phenotype of striatofugal medium spiny neurons in parkinsonian and dyskinetic nonhuman primates: a call for a reappraisal of the functional organization of the basal ganglia publication-title: J Neurosci doi: 10.1523/JNEUROSCI.2582-06.2006 – volume: 54 start-page: 1589 issue: 8 year: 2000 ident: 10.1016/S1353-8020(09)70783-7_bib16 article-title: AMPA receptor blockade improves levodopa-induced dyskinesia in MPTP monkeys publication-title: Neurology doi: 10.1212/WNL.54.8.1589 – volume: 28 start-page: 7113 issue: 28 year: 2008 ident: 10.1016/S1353-8020(09)70783-7_bib31 article-title: Differences between dorsal and ventral striatum in Drd1a dopamine receptor coupling of dopamine-and cAMP-regulated phosphoprotein-32 to activation of extracellular signal-regulated kinase publication-title: J Neurosci doi: 10.1523/JNEUROSCI.3952-07.2008 – volume: 28 start-page: 941 issue: 5 year: 2008 ident: 10.1016/S1353-8020(09)70783-7_bib10 article-title: Lowered cAMP and cGMP signalling in the brain during levodopa-induced dyskinesias in hemiparkinsonian rats: new aspects in the pathogenetic mechanisms publication-title: Eur J Neurosci doi: 10.1111/j.1460-9568.2008.06387.x – ident: 10.1016/S1353-8020(09)70783-7_bib26 doi: 10.1126/scitranslmed.3000664 – volume: 22 start-page: 5042 issue: 12 year: 2002 ident: 10.1016/S1353-8020(09)70783-7_bib27 article-title: D1 dopamine receptor supersensitivity in the dopamine-depleted striatum results from a switch in the regulation of ERK1/2/MAP kinase publication-title: J Neurosci doi: 10.1523/JNEUROSCI.22-12-05042.2002 – volume: 6 start-page: 501 issue: 5 year: 2003 ident: 10.1016/S1353-8020(09)70783-7_bib13 article-title: Loss of bidirectional striatal synaptic plasticity in L-DOPA-induced dyskinesia publication-title: Nat Neurosci doi: 10.1038/nn1040 – volume: 59 start-page: 64 issue: 1 year: 2006 ident: 10.1016/S1353-8020(09)70783-7_bib28 article-title: ERK phosphorylation and FosB expression are associated with L-DOPA-induced dyskinesia in hemiparkinsonian mice publication-title: Biol Psychiatry doi: 10.1016/j.biopsych.2005.05.044 – volume: 74 start-page: 59 issue: 1 year: 2008 ident: 10.1016/S1353-8020(09)70783-7_bib24 article-title: Reciprocal regulation of dopamine D1 and D3 receptor function and trafficking by heterodimerization publication-title: Mol Pharmacol doi: 10.1124/mol.107.043885 |
| SSID | ssj0007503 |
| Score | 1.9476383 |
| SecondaryResourceType | review_article |
| Snippet | Chronic L-3,4-dihydroxyphenylalanine (L-dopa) treatment of Parkinson Disease (PD) often leads to debilitating involuntary movements, termed L-dopa-induced... Summary Chronic L-3,4-dihydroxyphenylalanine (L-dopa) treatment of Parkinson Disease (PD) often leads to debilitating involuntary movements, termed... |
| SourceID | proquest pubmed crossref elsevier |
| SourceType | Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | S64 |
| SubjectTerms | Abnormal involuntary movements Animals Dopamine Agents - adverse effects Dopamine Agents - pharmacology Dopamine D1 receptor Dyskinesia, Drug-Induced - etiology Humans L-dopa Levodopa - adverse effects Levodopa - pharmacology Models, Biological Neurology Parkinson's disease Protein Transport - drug effects Receptors, Dopamine D1 - metabolism Sensitisation Signal Transduction - drug effects Signal Transduction - physiology Trafficking |
| Title | Involvement of canonical and non-canonical D1 dopamine receptor signalling pathways in L-dopa-induced dyskinesia |
| URI | https://www.clinicalkey.com/#!/content/1-s2.0-S1353802009707837 https://www.clinicalkey.es/playcontent/1-s2.0-S1353802009707837 https://dx.doi.org/10.1016/S1353-8020(09)70783-7 https://www.ncbi.nlm.nih.gov/pubmed/20083011 https://www.proquest.com/docview/733836963 |
| Volume | 15 |
| WOSCitedRecordID | wos000576252500015&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVESC databaseName: Elsevier SD Freedom Collection Journals 2021 customDbUrl: eissn: 1873-5126 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0007503 issn: 1353-8020 databaseCode: AIEXJ dateStart: 19950701 isFulltext: true titleUrlDefault: https://www.sciencedirect.com providerName: Elsevier |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1bb9MwFLa6DSFeEHfKZfIDD6DKkCZxHD9OW4EhmJA6pL5ZruOgipJWTbsL_4B_zTmxk7SMaQOJlyiy7DjJ-Xwu9rkQ8kIbzVHPZcZmnMUmyJnW3DLJTZbDQufROKuKTYijo3Q0kp87nZ91LMzJVBRFenYm5_-V1NAGxMbQ2b8gd_NQaIB7IDpcgexwvRbhDwvgOFUW8OqQH37drGhSAsA9a1sO-r0MjObvqGkC57NzMMB76NGhXaZuLFd8qs8rl9mPDLsyMOFX6DKQnZff0GN-otfVW4yhrsLJsPQGgqoKlcHuPslno8G_W02-zqpyUr19d1g_XT_htz-087kfLE49fuutCfmbm0cTM9M6KCGLjXgEcjF0pzHWtaUiYqB6JBt8ma8x1qHLde5l9NCV8LjA_t1OxLCZApR0zKcqMaVRxEQr8xpPxKovdg1cJ7FFdkLBJTDInb3DwehDI9bxwLey3v2z23CwN-2ELwP5yk92maJzmSFTKTTHd8htb4nQPYegu6Rji3vk5ifva3GfzNeARGc5bWBDAUh0A0j0oE9rINEaSLQFEq2BRCcF3QQSbYH0gHx5Ozjef898fQ5mYhEtWRqNZSzhq40ObZKFgdBAw9D281AmodGxSHUe5kLnaRibBHiFHAvLeWazLOmPo-gh2Yb3tI8JHXOZgrAxYcTjOI3MGPRq4Bk8BoaR2sx2SVz_TGV88nqsoTJVjZci0kAhDVQgVUUDJbrkdTNs7rK3XDUgqSml6tBkEKYKAHbVQPGngbb0nKFUfVWGKlAXANclaTPSa71Om73OpLQGkwKpgEd9urCzVakE7jwlIFy75JEDWfP96PCEUv3Jv8_7lNxql_szsr1crOxzcsOcLCflYpdsiVG665fPL2GH4ZU |
| linkProvider | Elsevier |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Involvement+of+canonical+and+non-canonical+D1+dopamine+receptor+signalling+pathways+in+L-dopa-induced+dyskinesia&rft.jtitle=Parkinsonism+%26+related+disorders&rft.au=Guigoni%2C+C%C3%A9line&rft.au=Bezard%2C+Erwan&rft.date=2009-12-01&rft.pub=Elsevier+Ltd&rft.issn=1353-8020&rft.eissn=1873-5126&rft.volume=15&rft.spage=S64&rft.epage=S67&rft_id=info:doi/10.1016%2FS1353-8020%2809%2970783-7&rft.externalDocID=S1353802009707837 |
| thumbnail_m | http://cvtisr.summon.serialssolutions.com/2.0.0/image/custom?url=https%3A%2F%2Fcdn.clinicalkey.com%2Fck-thumbnails%2F13538020%2FS1353802009X70033%2Fcov150h.gif |